[144] Axsome Therapeutics, Inc SEC Filing

Rhea-AI Filing Summary

Axsome Therapeutics, Inc. (AXSM) Form 144 notice reports a proposed sale of 13,464 common shares through Charles Schwab & Co., Inc. on 09/02/2025 on NASDAQ with an aggregate market value of $1,665,162.00. The filing lists the securities being sold as previously acquired by exercise and hold on 03/19/2019 (9,514 shares) and 11/19/2021 (3,950 shares), with cash payment noted. The filer also discloses five separate sales during August 2025 totaling 96,694 shares with gross proceeds shown for each trade. The notice includes the standard representation attesting no undisclosed material adverse information.

Insights

Securities Analyst

TL;DR: Routine insider sales disclosed; proposed sale is modest and follows multiple August 2025 dispositions.

The filing shows a proposed sale of 13,464 common shares via Charles Schwab on 09/02/2025 with an aggregate market value of $1,665,162.00. The securities were acquired by exercise on 03/19/2019 and 11/19/2021 and paid in cash. The filer also reported five sales in August 2025 totaling 96,694 shares with listed gross proceeds for each trade. From a market-impact perspective, these are standard rule 144 disclosures documenting insider liquidity rather than corporate action or financing.

Corporate Governance Expert

TL;DR: Disclosure complies with Rule 144; sales documented but no corporate governance changes reported.

The Form 144 provides required notice of proposed sales and past sales by the identified individual, including acquisition dates and nature (exercise and hold). It contains the customary signer representation about absence of undisclosed material adverse information and notes broker details. There is no information in the filing indicating management changes, new plans, or other governance actions; the document serves as transparent reporting of insider share dispositions.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Charles Schwab & Co., Inc. 3000 Schwab Way Westlake TX 76262	13464	1665162.00	49901487	09/02/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	03/19/2019	Exercise and Hold	Axsome Therapeutics, Inc.			9514	03/19/2019	Cash
Common	11/19/2021	Exercise and Hold	Axsome Therapeutics, Inc.			3950	11/19/2021	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
ROGER JEFFS ONE WORLD TRADE CENTER, 29TH FLOOR NEW YORK NY 10007	Axsome Therapeutics, Inc.	08/22/2025	16694	2004598.00
ROGER JEFFS ONE WORLD TRADE CENTER, 29TH FLOOR NEW YORK NY 10007	Axsome Therapeutics, Inc.	08/26/2025	20000	2400658.00
ROGER JEFFS ONE WORLD TRADE CENTER, 29TH FLOOR NEW YORK NY 10007	Axsome Therapeutics, Inc.	08/27/2025	20000	2446052.00
ROGER JEFFS ONE WORLD TRADE CENTER, 29TH FLOOR NEW YORK NY 10007	Axsome Therapeutics, Inc.	08/28/2025	20000	2432004.00
ROGER JEFFS ONE WORLD TRADE CENTER, 29TH FLOOR NEW YORK NY 10007	Axsome Therapeutics, Inc.	08/29/2025	20000	2425335.00

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What shares does the Form 144 for AXSM propose to sell?

The notice proposes to sell 13,464 shares of Axsome Therapeutics, Inc. common stock.

When and where is the proposed sale scheduled?

The proposed sale is listed for 09/02/2025 through Charles Schwab & Co., Inc. on NASDAQ.

What is the aggregate market value of the proposed sale?

The aggregate market value reported for the proposed sale is $1,665,162.00.

How were the securities being sold originally acquired?

The securities were acquired by exercise and hold on 03/19/2019 (9,514 shares) and 11/19/2021 (3,950 shares), paid in cash.

Did the filer make recent sales of AXSM shares?

Yes; the filing discloses five sales in August 2025 totaling 96,694 shares with gross proceeds detailed for each sale.